Followers | 63 |
Posts | 8502 |
Boards Moderated | 0 |
Alias Born | 01/10/2014 |
Thursday, December 10, 2020 12:23:07 PM
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, announced today that it has delivered the 100,000th whole human genome sequence dataset to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). Although Personalis has been contracted by the VA MVP since 2012, the program has accelerated and over 50,000 of these genomes have been delivered in 2020.
"The VA MVP is the largest whole genome sequencing project in the United States and this is a significant milestone for both the program and for Personalis," said John West, Chief Executive Officer. "Population-scale sequencing projects of this nature represent a cornerstone in our effort to accelerate the advancement of precision medicine across a wide range of disease areas. With our sizable investments in the technology and infrastructure, necessary to win and execute these projects, Personalis sees population genomics and health as key priorities for our company. We congratulate the VA MVP for their visionary leadership and note that VA scientists now list over 50 peer reviewed publications from the Program."
https://finance.yahoo.com/news/personalis-announces-delivery-100-000th-210700535.html
“Believing in negative thoughts is the single greatest obstruction to success.”
Charles F. Glassman
Statements made are only my opinion. Do your own DD in order to make your own investment decisions.
Recent PSNL News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 09:28:28 PM
- ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test • Business Wire • 09/16/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/12/2024 04:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/30/2024 08:43:07 PM
- Personalis to Participate at Upcoming Investor Conferences • Business Wire • 08/22/2024 08:01:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/20/2024 08:27:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 08:17:55 PM
- Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/19/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 01:25:01 PM
- Personalis and Tempus Announce Expanded Collaboration • Business Wire • 08/16/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:35:56 PM
- Personalis Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:00:09 PM
- Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12% • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:16:00 PM
- Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference • Business Wire • 07/31/2024 08:01:00 PM
- Personalis to Announce Second Quarter 2024 Financial Results • Business Wire • 07/24/2024 08:01:00 PM
- Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing • GlobeNewswire Inc. • 07/11/2024 01:00:00 PM
- Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference • Business Wire • 06/18/2024 08:01:00 PM
- Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call • Business Wire • 06/13/2024 12:00:00 PM
- ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring • Business Wire • 06/04/2024 08:05:00 PM
- Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus • Business Wire • 05/31/2024 01:05:00 PM
- Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024 • Business Wire • 05/22/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2024 01:14:13 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM